Application of gensenoside C-K to preparing medicines for treating psoriasis

A technology of ginsenosides and C-K, which is used in drug combinations, medical preparations containing active ingredients, skin diseases, etc.

Inactive Publication Date: 2017-07-07
SHANGHAI INST OF PHARMA IND +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] Salicylic acid: It has a certain curative effect, and there is no contraindication dosage prescribed by the FDA, but it should be used with caution in large areas, especially those with liver and kidney i...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gensenoside C-K to preparing medicines for treating psoriasis
  • Application of gensenoside C-K to preparing medicines for treating psoriasis
  • Application of gensenoside C-K to preparing medicines for treating psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1 ： CK Antiproliferative effect on human epidermal cells in vitro

[0060] This example illustrates that ginsenosides C-K (also referred to herein as CK for short) have the effect of inhibiting the proliferation of human epidermal cells in vitro. In this example, the CK was administered to the cells by dissolving in dimethyl sulfoxide, the human epidermal cells were human immortalized epidermal cells (HaCat cells), and MTT (3-(4,5-dimethylthiazole -2)-2,5-diphenyl tetrazolium bromide salt, trade name: thiazolium blue) method to detect the survival and growth of cells.

[0061] A CK sample (commercially available, Shanghai Standard Biotech Co., Ltd. purity 92%, Lot 3690 / 20548) was dissolved in dimethyl sulfoxide to obtain a solution with a concentration of 10 mg / ml. Then use PBS for gradient dilution to obtain diluted samples with concentrations of 1000 μg / ml, 100 μg / ml, 10 μg / ml, 1 μg / ml, 0.1 μg / ml, and 0.01 μg / ml. Cisplatin for injection (freeze-dried...

Embodiment 2

[0066] Example 2 ： CK Effects on the differentiation of human epidermal cells

[0067] This example illustrates the effect of ginsenosides C-K (CK) on the differentiation of human epidermal cells. In this example, the CK was administered to the cells by dissolving in dimethyl sulfoxide, the human epidermal cells were immortalized human epidermal cells (HaCat cells), and the differentiation of the cells was detected by immunohistochemical staining.

[0068] HaCat cells were cultured in DMEM medium (containing 10% FBS), and when reaching 80% of the culture flask area, after digestion with 0.25% trypsin, the cell concentration was adjusted to 8×10 4 / ml and transferred into 6-well plates (with sterilized glass slides added to the plates), and set the concentration of ginsenoside CK to 20 μg / ml, respectively added to the corresponding wells, and set a blank control, and placed the cells at 37°C In the incubator, the anti-keratin 18 / 19 antibody (provided by the Department ...

Embodiment 3

[0070] Example 3 ： CK neovascularization ( Angiogenesis of chick embryo allantoic membrane ) Has inhibitory effect

[0071] This example shows that ginsenosides C-K have inhibitory effects on chick embryo neovascularization (chick embryo allantoic membrane angiogenesis). In this embodiment, negative control substance-buffered saline (abbreviated as PBS), positive control substance-sorafenib hydrochloride (abbreviated as Sorafenib), and ginsenosides C-K were administered to chicken embryos respectively.

[0072] Sterilize the surgical instruments and filter papers used. Take fresh eggs and incubate continuously for 6 days at 37°C and 50% humidity. On the 6th day, it was identified whether the chicken embryos were viable, and the surviving eggs were taken out for window opening. First use light to locate the position of the allantoic membrane and make a mark, then make a small hole at the end of the egg air sac, place the egg with the allantoic membrane facing up...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to view more

Abstract

The invention provides application of gensenoside C-K and pharmacologically acceptable solvates or hydrates of the gensenoside C-K to preparing medicines for treating psoriasis, a medicine box and a medicine composition with the gensenoside C-K for treating the psoriasis and a method for preparing the medicine composition.

Description

[0001] Technical field: [0002] The invention provides the application of ginsenoside C-K and its pharmaceutically acceptable solvate or hydrate in the preparation of medicines for treating psoriasis, and the kit containing said ginsenoside C-K for treating psoriasis , a pharmaceutical composition, and a method for preparing the pharmaceutical composition. [0003] Background technique: [0004] "Psoriasis", also known as psoriasis, is a chronic, relapsing, inflammatory disease of the skin with clear edges, erythema, thickened skin, and covered with scales; it is stubborn and easy to relapse. Psoriasis can affect the whole body of the patient, but it is more common on the scalp, extensor sides of the extremities, and the back. The clinical symptoms showed that the patient had erythema, dry scales appeared repeatedly on the erythema, and there were bleeding spots after the scales fell off. [0005] The incidence of psoriasis varies greatly around the world. The incidence rate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7032A61P17/06
CPCA61K31/7032
Inventor 刘全海刘珉宇邓轶方黄晓玲余增洋于鹏霞
Owner SHANGHAI INST OF PHARMA IND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap